Literature DB >> 19667109

Renal dysfunction potentiates foam cell formation by repressing ABCA1.

Yiqin Zuo1, Patricia Yancey, Iris Castro, Wasif N Khan, Wasif Khan, Masaru Motojima, Iekuni Ichikawa, Agnes B Fogo, MacRae F Linton, Sergio Fazio, Valentina Kon.   

Abstract

OBJECTIVE: Patients with chronic kidney disease (CKD) have the highest risk for atherosclerotic cardiovascular disease (CVD). Current interventions have been insufficiently effective in lessening excess incidence and mortality from CVD in CKD patients versus other high-risk groups. The mechanisms underlying the heightened risk remain obscure but may relate to differences in CKD-induced atherogenesis, including perturbation of macrophage cholesterol trafficking. METHODS AND
RESULTS: We examined the impact of renal dysfunction on macrophage cholesterol homeostasis in the apoE(-/-) mouse model of atherosclerosis. Renal impairment induced by uninephrectomy dramatically increased macrophage cholesterol content, linked to striking impairment of macrophage cholesterol efflux. This blunted efflux was associated with downregulation of the cholesterol transporter ATP-binding cassette transporter A1 (ABCA1) and activation of the nuclear factor-kappa B (NF-kappaB). Treatment with the angiotensin receptor blocker (ARB) losartan decreased NF-kappaB and restored cholesterol efflux.
CONCLUSIONS: Our findings show that mild renal dysfunction perturbs macrophage lipid homeostasis by inhibiting cholesterol efflux, mediated by decreased ABCA1 transporter and activation of NF-kappaB, and that ARB can restore cholesterol efflux.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19667109      PMCID: PMC2748735          DOI: 10.1161/ATVBAHA.109.188995

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  46 in total

Review 1.  Regulation and mechanisms of macrophage cholesterol efflux.

Authors:  Alan R Tall; Philippe Costet; Nan Wang
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

2.  Angiotensin blockade inhibits increased JNKs, AP-1 and NF- kappa B DNA-binding activities in myocardial infarcted rats.

Authors:  M Yoshiyama; T Omura; K Takeuchi; S Kim; K Shimada; H Yamagishi; M Teragaki; K Akioka; H Iwao; J Yoshikawa
Journal:  J Mol Cell Cardiol       Date:  2001-04       Impact factor: 5.000

3.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

4.  The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice.

Authors:  Charles W Joyce; Marcelo J A Amar; Gilles Lambert; Boris L Vaisman; Beverly Paigen; Jamila Najib-Fruchart; Robert F Hoyt; Edward D Neufeld; Alan T Remaley; Donald S Fredrickson; H Bryan Brewer; Silvia Santamarina-Fojo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

5.  LXR-induced reverse cholesterol transport in human airway smooth muscle is mediated exclusively by ABCA1.

Authors:  Christopher J Delvecchio; Patricia Bilan; Parameswaran Nair; John P Capone
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-09-26       Impact factor: 5.464

6.  Angiotensin II reduces macrophage cholesterol efflux: a role for the AT-1 receptor but not for the ABC1 transporter.

Authors:  Marielle Kaplan; Michael Aviram; Carlos Knopf; Shlomo Keidar
Journal:  Biochem Biophys Res Commun       Date:  2002-02-08       Impact factor: 3.575

7.  A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux.

Authors:  Carl P Sparrow; Joanne Baffic; My-Hanh Lam; Erik G Lund; Alan D Adams; Xuan Fu; Nancy Hayes; A Brian Jones; Karen L Macnaul; John Ondeyka; Sheo Singh; Jianhua Wang; Gaochao Zhou; David E Moller; Samuel D Wright; John G Menke
Journal:  J Biol Chem       Date:  2002-01-14       Impact factor: 5.157

8.  Lipopolysaccharide down regulates both scavenger receptor B1 and ATP binding cassette transporter A1 in RAW cells.

Authors:  Irina Baranova; Tatyana Vishnyakova; Alexander Bocharov; Zhigang Chen; Alan T Remaley; John Stonik; Thomas L Eggerman; Amy P Patterson
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

Review 9.  Importance of different pathways of cellular cholesterol efflux.

Authors:  Patricia G Yancey; Anna E Bortnick; Ginny Kellner-Weibel; Margarita de la Llera-Moya; Michael C Phillips; George H Rothblat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-01-23       Impact factor: 8.311

10.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

Authors:  Rory Collins; Jane Armitage; Sarah Parish; Peter Sleigh; Richard Peto
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

View more
  19 in total

Review 1.  Foam cells and the pathogenesis of kidney disease.

Authors:  Minseob Eom; Kelly L Hudkins; Charles E Alpers
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-05       Impact factor: 2.894

2.  Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.

Authors:  Suguru Yamamoto; Jiayong Zhong; Patricia G Yancey; Yiqin Zuo; MacRae F Linton; Sergio Fazio; Haichun Yang; Ichiei Narita; Valentina Kon
Journal:  Atherosclerosis       Date:  2015-07-04       Impact factor: 5.162

Review 3.  Chronic kidney disease as a coronary artery disease risk equivalent.

Authors:  Alexandrios Briasoulis; George L Bakris
Journal:  Curr Cardiol Rep       Date:  2013-03       Impact factor: 2.931

4.  Uremic Toxin Indoxyl Sulfate Promotes Proinflammatory Macrophage Activation Via the Interplay of OATP2B1 and Dll4-Notch Signaling.

Authors:  Toshiaki Nakano; Shunsuke Katsuki; Mingxian Chen; Julius L Decano; Arda Halu; Lang Ho Lee; Diego V S Pestana; Angelo S T Kum; Rodrigo K Kuromoto; Whitney S Golden; Mario S Boff; Gabriel C Guimaraes; Hideyuki Higashi; Kevin J Kauffman; Takashi Maejima; Takehiro Suzuki; Hiroshi Iwata; Albert-László Barabási; Jon C Aster; Daniel G Anderson; Amitabh Sharma; Sasha A Singh; Elena Aikawa; Masanori Aikawa
Journal:  Circulation       Date:  2019-01-02       Impact factor: 29.690

5.  Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice.

Authors:  Hagai Tavori; Daping Fan; Ilaria Giunzioni; Lin Zhu; MacRae F Linton; Agnes B Fogo; Sergio Fazio
Journal:  J Lipid Res       Date:  2014-09-02       Impact factor: 5.922

Review 6.  Extracellular vesicles as mediators of vascular inflammation in kidney disease.

Authors:  Alexandra Helmke; Sibylle von Vietinghoff
Journal:  World J Nephrol       Date:  2016-03-06

7.  Increased atherosclerotic lesion formation and vascular leukocyte accumulation in renal impairment are mediated by interleukin-17A.

Authors:  Shuwang Ge; Barbara Hertel; Ekaterina K Koltsova; Inga Sörensen-Zender; Jan T Kielstein; Klaus Ley; Hermann Haller; Sibylle von Vietinghoff
Journal:  Circ Res       Date:  2013-08-01       Impact factor: 17.367

8.  Moderate kidney disease inhibits atherosclerosis regression.

Authors:  Manish P Ponda; Irina Barash; Jonathan E Feig; Edward A Fisher; Edward Y Skolnik
Journal:  Atherosclerosis       Date:  2009-10-29       Impact factor: 5.162

9.  Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden.

Authors:  Jason R Stubbs; John A House; A Jacob Ocque; Shiqin Zhang; Cassandra Johnson; Cassandra Kimber; Kyle Schmidt; Aditi Gupta; James B Wetmore; Thomas D Nolin; John A Spertus; Alan S Yu
Journal:  J Am Soc Nephrol       Date:  2015-07-30       Impact factor: 10.121

Review 10.  Cholesterol Metabolism in CKD.

Authors:  Allison B Reiss; Iryna Voloshyna; Joshua De Leon; Nobuyuki Miyawaki; Joseph Mattana
Journal:  Am J Kidney Dis       Date:  2015-09-01       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.